Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial.
Máté VámosJonas OldgrenGi-Byoung NamGregory Y H LipHugh CalkinsJun ZhuKwo-Chang UengUlf LudwigsMattias WielochJohn StewartStefan H HohnloserPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
Dronedarone is an effective AAD in patients with AF/AFL and CV risk factors across a wide range of renal function.